about
sameAs
The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohortLong-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.The time of DMARD start in Juvenile Idiopathic Arthritis determines the likelihood of a drug-free remission in young adulthood
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jens Klotsche
@ast
Jens Klotsche
@en
Jens Klotsche
@es
Jens Klotsche
@nl
type
label
Jens Klotsche
@ast
Jens Klotsche
@en
Jens Klotsche
@es
Jens Klotsche
@nl
prefLabel
Jens Klotsche
@ast
Jens Klotsche
@en
Jens Klotsche
@es
Jens Klotsche
@nl
P106
P31
P496
0000-0002-2954-5755